ArticleHSS journal : the musculoskeletal journal of Hospital for Special Surgery2013
Use of imatinib in the prevention of heterotopic ossification.
Article in HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Mast cell activation by NGF drives the formation of trauma-induced heterotopic ossification.JCI insight · 2024Article
- Review
- Tourniquet use following blast-associated complex lower limb injury and traumatic amputation promotes end organ dysfunction and amplified heterotopic ossification formation.Journal of orthopaedic surgery and research · 2022Article
- Review
- Case Report: Two Monochorionic Twins With a Critically Different Course of Progressive Osseus Heteroplasia.Frontiers in pediatrics · 2021Article
- Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.Disease models & mechanisms · 2020Review
- Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP).Bone · 2018Article
- PDGF is a potent initiator of bone formation in a tissue engineered model of pathological ossification.Journal of tissue engineering and regenerative medicine · 2018Article
- Serum biomarkers in patients with ossification of the posterior longitudinal ligament (OPLL): Inflammation in OPLL.PloS one · 2017Article
- Defining the Balance between Regeneration and Pathological Ossification in Skeletal Muscle Following Traumatic Injury.Frontiers in physiology · 2017Review
- Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Article
- Prevention of heterotopic ossification: an experimental study using a plasma expander in a murine model.BMC surgery · 2016Article
- The immunological contribution to heterotopic ossification disorders.Current osteoporosis reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeterotopic ossification (HO) is a common complication following orthopedic and trauma surgery, which may have substantial negative effects on the postoperative outcome. Angiogenesis appears to play a critical role in heterotopic ossification. One of the involved signaling molecules is platelet-derived growth factor (PDGF) which may be inhibited by imatinib. QUESTIONS/PURPOSES: Our goal was to prevent HO by pharmacologically interfering with the molecular signaling pathways involved in the developmental process. We hypothesized that by administering a proven inhibitor of PDGF expression, heterotopic bone formation may be prevented.
methodsThe effect of imatinib on HO formation was studied in a murine model which reliably produces islets of HO within the soft tissue following Achilles tenotomy. The control group underwent Achilles tenotomy only. The imatinib group received imatinib mesylate. After trial completion, the limbs were harvested and scanned by micro-CT. Heterotopic bone volume was then identified and quantified.
resultsThe mean volume of heterotopic bone formed in the control group was 0.976mm(3) compared to 0.221 mm(3) in the imatinib group. The volume of HO in the treatment group was reduced by 85% compared to the control group.
conclusionsThe administration of imatinib was associated with a significantly reduced volume of HO. This may be due to the inhibitory effect of imatinib on the PDGF signaling pathway during development of HO. CLINICAL RELEVANCE: The successful reduction of HO formation following imatinib administration has led to further insight concerning the pathogenesis of HO which in the future may lead to new clinical approaches towards the prevention of HO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.